High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer

摘要: The involvement of alarmin high-mobility group nucleosome-binding protein 1 (HMGN1) in non-small cell lung cancer (NSCLC) is unknown. To address the presence HMGN1 serum different stages NSCLC patients and healthy controls, we enrolled a consecutive sample adult at diagnosis correlated it with clinicopathologic outcomes. A total 100 23 volunteers were from January 2012 through December 2013. Serum levels determined by enzyme-linked immunosorbent assay (ELISA). Additionally, 50 early-stage disease who received curative pneumonectomy survivals. Kaplan-Meier plots used to analyze data. characterized significantly higher (0.4585 ± 0.0640 ng/ml) compared those controls (0.3578 ± 0.0304 ng/ml). 0.4027 ± 0.0271 ng/ml, 0.4604 ± 0.0328 ng/ml, 0.5408 ± 0.0459 ng/ml, 0.4213 ± 0.0341 ng/ml TNM I, II, IV, respectively (p < 0.001). There significant differences among four groups positive correlation between tumor stage was found local disease, while level metastatic decreased. showed that high had poorer overall survival (OS) after than low (p = 0.019). Inflammation triggered alarmins plays role pathogenesis. can serve as useful clinical parameter for evaluating progression predicting outcomes undergoing pneumonectomy.